Monitoring Clinical Trials

SOP Reference: RGIT_SOP_015

Version Number: 8.0

Effective Date: 19 Oct 2020  Review by: 19 Oct 2023

Author: Sarangan Ragulan, Clinical Trials Monitor

Approved by: Ruth Nicholson, Head of Research Governance and Integrity

Date: Digitally signed by Ruth Nicholson

Date: 2020.10.14 09:45:47 +01'00'

<table>
<thead>
<tr>
<th>Version</th>
<th>Date</th>
<th>Reason for Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Version 1.0</td>
<td>31 May 2007</td>
<td>1st Edition</td>
</tr>
<tr>
<td>Version 2.0</td>
<td>19 Jun 2008</td>
<td>Annual review</td>
</tr>
<tr>
<td>Version 3.0</td>
<td>08 Feb 2010</td>
<td>Formation of Joint Research Office</td>
</tr>
<tr>
<td>Version 4.0</td>
<td>14 Jul 2011</td>
<td>Annual review</td>
</tr>
<tr>
<td>Version 5.0</td>
<td>30 Nov 2012</td>
<td>Annual Review</td>
</tr>
<tr>
<td>Version 6.0</td>
<td>18 Feb 2015</td>
<td>Scheduled Review</td>
</tr>
<tr>
<td>Version 7.0</td>
<td>25 Oct 2017</td>
<td>Scheduled Review</td>
</tr>
<tr>
<td>Version 8.0</td>
<td>19 Oct 2020</td>
<td>Scheduled Review Templates removed and administrative changes to SOP. JRCO name change to RGIT</td>
</tr>
</tbody>
</table>
# TABLE OF CONTENTS

1. PURPOSE .................................................................................................................................................. 3
2. INTRODUCTION .......................................................................................................................................... 3
3. RESPONSIBILITIES ...................................................................................................................................... 4
4. PROCEDURE .................................................................................................................................................. 4
   4.1. Qualification of monitors .......................................................................................................................... 4
   4.2. Types of monitoring .................................................................................................................................. 4
   4.3. Extent of monitoring ................................................................................................................................ 7
   4.4. Monitor’s responsibilities ........................................................................................................................ 8
   4.5. Monitoring report ..................................................................................................................................... 8
   4.6. Trial Oversight committees ...................................................................................................................... 8
5. REFERENCES ................................................................................................................................................ 9
6. APPENDICES ................................................................................................................................................ 9
1. PURPOSE

The purpose of this Standard Operating Procedure (SOP) is to describe the monitoring procedures for clinical trials sponsored by Imperial College Academic Health Science Centre (AHSC).

2. INTRODUCTION

Monitoring is defined in The International Conference on Harmonisation of Good Clinical Practice (ICH GCP) guidelines as:

“The act of overseeing the progress of a clinical trial, and of ensuring that it is conducted, recorded, and reported in accordance with the protocol, SOPs, GCP, and the applicable regulatory requirement(s)”, ICH GCP, section 1.38

Section 5.18 of ICH GCP states in detail the minimum requirements for monitoring of clinical trials.

The purpose of monitoring is to verify that:

- The rights and well-being of the human subjects are protected
- The reported trial data are accurate, complete, and verifiable from source documents
- The conduct of the trial is in compliance with the currently approved protocol/amendment(s), with GCP, and with the applicable regulatory requirements.

Monitoring is an integral role in the Quality Control (QC) of a clinical trial and is designed to verify the quality of the study. Audits are designed to assess and assure the reliability and integrity of a trial’s quality control systems and are a way of measuring performance against recognised standards (Quality Assurance or QA). For further information on audits, consult RGIT_SOP_018.

Monitoring is usually performed by the Research Governance and Integrity Team (RGIT) monitors, an appropriately trained member of the study team/trial coordinating centre or by a contracted external monitor and should be designated on the study delegation log.

The involvement of Contracted External Monitor(s), the RGIT monitors, and the CI or PI in monitoring the Imperial College AHSC sponsored CTIMP studies will depend on whether the study is taking place in the AHSC hospitals, the College associated NHS Trusts or outside both the AHSC sites and the College associated NHS Trusts.

The Imperial College AHSC sites comprise of:
- Charing Cross Hospital;
- Hammersmith Hospital;
- Queen Charlotte’s and Chelsea Hospital;
- St Mary’s Hospital and
- Western Eye Hospital.

While the College associated NHS Trusts are:
- Royal Brompton and Harefield NHS Trust;
- Chelsea and Westminster Hospital NHS Foundation Trust and
- North West London Hospitals NHS Trust.

A Contracted External Monitor is defined in this context as any individual qualified by training and experience and who is not employed by the RGIT, Imperial College AHSC but is contracted to carry out clinical research monitoring in accordance with the GCP principles [see monitoring definition above].
3. RESPONSABILITIES

All Clinical Trials Sponsored by the AHSC taking place at the AHSC sites and the College associated NHS Trusts will be monitored as described in this SOP. Monitoring will be conducted by the RGIT Clinical Trials Monitor and overseen by the RGIT Clinical Trials Manager or delegate.

For AHSC sponsored clinical trials which do not take place in any of the AHSC sites and/or College Associated NHS Trust the Chief Investigator (CI) or Principle Investigator (PI) has the responsibility to make appropriate monitoring arrangements. This equally applies to all studies in the AHSC sites and the College associated NHS Trusts with Contracted External Monitors. The RGIT monitor must inform the CI of the RGIT monitoring requirements during a meeting or via email. The RGIT requirements include providing the monitor with the following information:

- Contact details of the external(s) Monitor at the site;
- Copy of the Monitor(s) contract for the study (if applicable) or job description;
- Copy of the Monitor(s) signed and dated CV;
- External/local Monitor monitoring plan
- Detailed report of all monitoring conducted

AHSC sponsored clinical trials conducted through the Imperial College Trials Unit (ICTU) will follow their monitoring and SOPs. ICTU will be responsible for assessing the suitability of trial monitors, conducting the risk assessment and compiling the monitoring plan. ICTU will provide the RGIT monitor with a copy of the monitoring plan prior to the trial commencement and will provide the RGIT with copies of the monitoring reports as stipulated in the monitoring plan. The RGIT will carry out the study start and close out visit.

The RGIT will review all monitoring reports from external/local/ICTU Monitors to uphold Sponsor requirements and will advise if there are any queries. This may be on a periodic basis as agreed with the vendor. The CI or PI must ensure that all the above requirements are met.

4. PROCEDURE

4.1. Qualification of monitors
Monitors should be appropriately trained and should have the scientific and/or clinical knowledge needed to monitor the trial adequately. A monitor’s qualifications should be documented. Training records, including relevant qualifications, should be kept by the monitor and checked by the Chief Investigator. For further information on training records, see RGIT_SOP_024.

The monitor should be familiar with the Investigational Medicinal Product (IMP), the protocol, information sheet and consent form, as well as the Imperial College AHSC SOPs, GCP and applicable regulatory requirements.

4.2. Types of monitoring

4.2.1 Coordinating Centre day-to-day monitoring
Day-to-day monitoring should be carried out by those responsible for running the study. This would normally include the following checks:

- Data collected are consistent with the protocol
- The case report forms (CRFs) are only being completed by authorised staff
- No key data is missing
- Data appears to be valid (e.g. within range and is consistent)
- A review of recruitment rates, withdrawals and losses to follow-up

4.2.2 Central Monitoring
Centralised procedures can be used to confirm patient eligibility (usually through the collection of pathology reports to substantiate a diagnosis), to corroborate the existence of the patient (for example, through The Office for National Statistics (ONS) flagging or collection of an imaging investigation) and to determine the outcome (for example, ONS flagging for survival end-points or central assessment of the results of an investigation, such as a X-ray or scan).

In large, multi-centre trials, central monitoring of data using statistical techniques is particularly useful for the early identification of:

- Unusual patterns or trends
- Issues with plausibility or consistency
- Safety signals
- Other deviation from the protocol/trial requirements such as poor/late completion of CRFs.

Where centralised monitoring indicates problems, it can be used to efficiently direct on-site monitoring activities to those sites requiring further investigation and/or additional training support. Although omissions (e.g. failure to report a serious adverse event (SAE)) or data entry errors cannot be detected directly, it may be possible to compare data from the different sites to identify sites that warrant investigation.

Examples of central statistical monitoring checks include:

1. Missing or invalid data
   Range checks can be used to identify unlikely or implausible values, such as extreme values for weight, or diastolic greater than systolic blood pressure. For trials using electronic data capture methods, these checks can usefully be built into the data collection form; any such automatic safeguards should be validated to ensure that they function correctly.

2. Calendar checks
   Examining the day of the week that patients were randomised can be revealing (e.g. randomisation on Sunday in a trial of patients attending outpatient clinic). It is also helpful to compare the order of trial forms (particularly if they have an ordered numbering system) with the dates they were completed.

3. Unusual data patterns
   Data from one site can be compared with data for the trial as a whole to identify patterns such as digit preference, rounding, or unusual frequency distribution (e.g. mean, variance, skewness). Such checks can be applied both to a single variable (e.g. systolic blood pressure) and to the joint distribution of several variables (e.g. systolic blood pressure and weight).

4. Rates of reporting
   The frequency of reported adverse events and of missing data can be compared between centres.

5. Repeated measures
   Where the same variable is measured on multiple occasions for each participant during the trial, it is possible to check that the variability and within individual changes of such repeated measurements is broadly consistent with the pattern seen for the trial as a whole.

6. Comparison with external sources
Checks with birth and death registries or with disease-specific registries (e.g. cancer registry) can be used to identify that particular patients exist and that particular events have (or have not) occurred.

In applying all these checks, it is important to recognise that some variability is to be expected. Data that is “too good” should raise suspicion in the same way as data that is unusually poor.

4.2.3 On-site monitoring

On-site monitoring visits may be used in a variety of different ways:

- to educate staff about the trial; review understanding of the protocol and trial procedures;
- to verify that the staff at the site have access to the necessary documents to conduct the trial;
- to ensure that the required pharmacy and laboratory resources are adequate;
- to check adherence to the protocol and GCP by reviewing such things as signed consent forms and patient eligibility;
- to verify all protocol required data (e.g. adverse event/concomitant medication) have been recorded on the CRFs and compared with data in the clinical records to identify errors of omission as well as inaccuracies.
- To check trial procedures (e.g. informed consent procedures, data collection, CRF completion) to ensure quality and consistency and confirm all assessments are being made by appropriately qualified staff;
- To identify staff training needs.

4.2.3.1 On-site Visits

a) Site Initiation Visit

The RGIT Trial Monitor will perform the SIV at all Imperial College London/Imperial College Healthcare NHS Trust research sites. The SIV for all other research sites must be conducted by an external monitor or appropriate member of the lead research team. An SIV cannot be performed until there is assurance that site agreement(s), all other relevant regulatory approvals and sponsorship greenlight is in place.

The SIV will be arranged so that the CI/PI and other key members of the study team can attend e.g. Study doctor, research nurse and pharmacist etc. a list of attendees will be collected.

A presentation will be given to the site to detail the responsibilities of the research team, as required by the sponsor. This will include at least the following:

- GCP and staff training
- The Informed Consent Process
- Safety Reporting
- Investigational Medicinal Product
- Protocol deviations and violations
- Trial Documentation
- Data Entry
- Laboratory
- Equipment calibration certificate or sop to demonstrate calibration is done
- Annual Reports
- Amendments
- End of Study
- Trial-specific procedures
The RGIT Monitor will check that all the documents required for the study to start the research are present. If the monitor is satisfied that all documents are present, the CI can sign the Study Start Approval form (SSA form), previous signed by the RGIT Clinical Trials Manager. Otherwise, the SSA for will be withheld pending a successful SIV.

b) Routine Monitoring Visit

The monitor will perform the following activities during each site monitoring visit:

- Review subject all informed consent forms
- Complete SDV as per requirements of the monitoring plan
- Review data quality
- Review the Trial Master File
- Review essential documents
  - Ensure the SAE log is complete and filed
  - Ensure that all Ethics reporting requirements have been met
- Review trial logs have been updated
- Discussion with the site staff and principle investigator on new issues and unresolved issues from monitoring visit, patient recruitment, site’s compliance to protocol…Review pharmacy file and check temperature logs
- Review Delegation of Duties and Site Signature Log

After the monitoring visit the RGIT Monitor will write the monitoring report including a list of all missing documents and issues raised that need to be resolved. This should be completed and sent to the site within 2 weeks and a response received from the site no later than 30 days after they’ve received the report.

c) Site Close Out Visit (COV)

A COV will be performed after the trial has been completed (or if the study has terminated early). The Trial Monitor will arrange the visit at a convenient date and time with the site staff and notify them in writing. At sites which are not part of the Imperial College Healthcare Trust the delegated monitor will need to perform the close out visits.

The COV will comprise of full site file review and source data verification. It will also include ensuring that all listed actions from previous monitoring visits are resolved. The monitor will ensure data entry is complete and that all outstanding queries are resolved.

The pharmacy file will also be closed, and a final accountability of IMP stock and returns will be conducted. Destruction of any remaining IMP will need to be approved by the CI/PI. The trial monitor will discuss archiving requirements with the study team and provide assistance where required. Results reporting and upload to EudraCT will also be reviewed with the study team.

After the Close Out monitoring visit the RGIT Monitor will write the monitoring report including a list of all missing documents and issues raised that need to be resolved.

4.3. Extent of monitoring

The sponsor should ensure that the trials are adequately monitored and determine the appropriate extent and nature of monitoring. This should be based on the objective, purpose, design, size, complexity, blinding, endpoints and risks associated with the clinical trial a CTIMP study is assessed as “high risk” or is First in Mankind which is automatically considered to be “high risk" the RGIT monitor will agree the frequency of routine monitoring visits with the CI of the study.

4.3.1 Risk Assessment

Appendix 1 contains an example Risk Assessment form that can be used by CI’s to suggest the appropriate level of monitoring for your study and to identify risks that may not have been considered in protocol development.
Based on the Risk Assessment a Monitoring Plan will be put in place by the RGIT Team describing all monitoring activity for the Clinical Trial. The Monitoring Plan needs to be agreed with the CI. In general, for most studies there will be a need for on-site monitoring, however, in some academic clinical trials and extenuating circumstances, the CI in conjunction with the RGIT, may decide that remote monitoring and self-assessed monitoring alongside relevant training and meetings with extensive written guidance can assure appropriate conduct of the trial. The RGIT will conduct a separate risk assessment as part of its study set-up process and will advise the CI on the recommended level of monitoring.

4.4. Monitor’s responsibilities

Monitors, in accordance with the Sponsor’s requirements, should ensure that the trial is conducted and documented properly by carrying out as a minimum the following activities:

- Ensuring that data collected is consistent with adherence to the protocol
- Case Report Forms (CRFs) are being completed by authorised personnel as designated by the delegation log
- No key data is missing
- Data appears to be valid (i.e. within range and consistent)
- Check adherence to protocol and GCP
- Verify selected items recorded on CRFs match data in participants’ health records
- Confirm that the participant has provided written consent

Full details of the monitor’s responsibilities as noted in section 5.18.4 of ICH GCP can be found in Appendix 2.

4.5. Monitoring report

Following the monitoring visit, the monitors should provide to the CI, pharmacy and the RGIT copies of all monitoring reports which should include:

- Date, site, name of monitor
- Name of CI/Principal Investigator or other site personnel in attendance
- Summary of documents the monitor has reviewed, along with significant findings, deviations (if applicable), deficiencies, actions taken or recommended. When a protocol violation is identified the sponsor will advise on what action is required and may initiate a triggered audit.

For IMP trials requiring MHRA approval, should the violation be identified as a serious breach, the Sponsor will inform the MRHA of the incident within seven days.

4.6. Trial Oversight committees

The funding body or sponsor may specify particular oversight arrangements. But even if they do not, some form of oversight is strongly recommended for all trials, although the appropriate structures will vary according to the size, complexity and risks associated with the trial.

Commonly employed oversight committees for a phase III trial include:

4.6.1 Trial Management Group (TMG)

Most trials should have a TMG, although in simpler trials this may comprise only one individual: the CI. For larger studies, this normally includes individuals who are responsible for the day-to-day management of the trial (e.g. the CI, trial coordinator, statistician, research nurse, data manager). The group’s role is to monitor all aspects of the conduct and progress of the trial, ensure that the protocol is adhered to and take appropriate action to safeguard participants and the quality of the trial itself.

4.6.2 Data Monitoring Committee (DMC)

A DMC should be considered for all trials, although one may not be always necessary (e.g. non-first in man phase I/II studies). DMCs should be set up for all phase III clinical trials. Its role is to review the accruing trial data and to assess whether there are any safety issues that should be brought to the attention of the TSC or any ethical reasons why the trial should not continue. The sponsor may consider establishing an
independent data-monitoring-committee (IDMC) to assess the progress of a clinical trial, including the safety data and the critical efficacy endpoints at intervals and to recommend to the sponsor whether to continue, modify, or stop a trial (ICH GCP 5.5.2) also to assess whether there are any safety issues that should be brought to participants’ attention.

The DMC should be the only body that has access to unblinded data.

DMCs might consider using the DAMOCLES Charter proposed in the Lancet 2005 as a model for the organisation of the IDMC.

4.6.3 Trial Steering Committee (TSC)
The role of a TSC is to provide overall supervision of the trial and ensure that it is being conducted in accordance with the principles of GCP and the relevant regulations. It should agree the trial’s protocol and any protocol amendments and provide advice to the investigators on all aspects of the trial.

The TSC will usually have members who are independent of the investigators, e.g. an independent chairperson. All documentation produced by the TSC will include key decisions made during the trial and should be archived in the Trial Master File (TMF).

Trial teams must send meeting minutes from TMG, TSC and DMC meetings to the RGIT for review. The RGIT should review the meeting minutes and confirm that there are no immediate actions arising from this meeting with regards to sponsor oversight.

5. REFERENCES

RGIT_SOP_018: Audit
RGIT_SOP_024: Training

CT-Toolkit: Trial Management & Monitoring


ICH GCP (1996), Section 1.8, 5.18 and 5.5.2

NHS R&D Forum. Distinguishing different types of Monitoring and Audit, November 2008

JRO UK regulations Compliance form (Part 2), version 1.0

6. APPENDICES

The following Appendices list the following Templates associated to this SOP which can be found on the SOP, Associated Documents & Templates page.

Appendix 1: Monitoring Risk Assessment – RGIT_TEMP_029
Appendix 2: Monitor’s responsibilities under ICH GCP – RGIT_TEMP_030